Global CD137 Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CD137 Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
CD137 Antibody is an antibody directed against the CD137 (also known as 4-1BB) protein in the human immune system.
CD137 Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD137 Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Demand from Flow Cytometry and ELISA are the major drivers for the industry.
CD137 is a cell surface molecule that belongs to the tumor necrosis factor receptor superfamily and is mainly expressed on activated T cells, natural killer cells and certain antigen-presenting cells. After binding to its ligand, CD137 can promote the proliferation, survival and cytotoxic response of T cells, thereby enhancing the immune response. Combining CD137 antibody with CD137 molecule may have a potential role in immunotherapy, which can be used to enhance anti-tumor immune response and treat diseases such as infection and tumor. Therefore, CD137 antibodies have attracted much attention in immunotherapy research and are regarded as one of the potential therapeutic strategies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD137 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Sino Biological, Inc.
Thermo Fisher
LifeSpan BioSciences, Inc
BioLegend
Abcam
Bio-Techne
GeneTex
Bio-Rad Laboratories, Inc.
Arigo Biolaboratories Corp.
Merck
Cell Signaling Technology, Inc.
MyBiosource, Inc.
Boster Biological Technology
Biocare Medical, LLC
Signalway Antibody LLC
NSJ Bioreagents
Leinco Technologies
Wuhan Fine Biotech Co., Ltd.
Elabscience Biotechnology Inc.
Biotium
Bioss Inc
Miltenyi Biotec
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Flow Cytometry
ELISA
Immunoprecipitation
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD137 Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD137 Antibody introduction, etc. CD137 Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of CD137 Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
CD137 Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD137 Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Demand from Flow Cytometry and ELISA are the major drivers for the industry.
CD137 is a cell surface molecule that belongs to the tumor necrosis factor receptor superfamily and is mainly expressed on activated T cells, natural killer cells and certain antigen-presenting cells. After binding to its ligand, CD137 can promote the proliferation, survival and cytotoxic response of T cells, thereby enhancing the immune response. Combining CD137 antibody with CD137 molecule may have a potential role in immunotherapy, which can be used to enhance anti-tumor immune response and treat diseases such as infection and tumor. Therefore, CD137 antibodies have attracted much attention in immunotherapy research and are regarded as one of the potential therapeutic strategies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD137 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Sino Biological, Inc.
Thermo Fisher
LifeSpan BioSciences, Inc
BioLegend
Abcam
Bio-Techne
GeneTex
Bio-Rad Laboratories, Inc.
Arigo Biolaboratories Corp.
Merck
Cell Signaling Technology, Inc.
MyBiosource, Inc.
Boster Biological Technology
Biocare Medical, LLC
Signalway Antibody LLC
NSJ Bioreagents
Leinco Technologies
Wuhan Fine Biotech Co., Ltd.
Elabscience Biotechnology Inc.
Biotium
Bioss Inc
Miltenyi Biotec
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Flow Cytometry
ELISA
Immunoprecipitation
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD137 Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD137 Antibody introduction, etc. CD137 Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of CD137 Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices